WLBU2 

WLBU2 is a engineered cationic antimicrobial peptide (eCAP) that overcomes the environmental sensitivity of natural antimicrobial peptides (AMPs). WLBU2 exhibits rapid bactericidal effect, with the MIC values of ≤ 10 μM against both Gram-negative and Gram-positive bacteria including MRSA, vancomycin-resistant enterococci, K. pneumoniae, E.aerogenes, E. cloacae, Escherichia coli, et, al. WLBU2 prevents P. aeruginosa biofilm growth and retains its activity in an environment rich in mucus, low pH and high salt concentrations without negative effects on human airway epithelial cells. WLBU2 can be used for the studies of cystic fibrosis (CF) and Pseudomonas aeruginosa infections^[1][2].

WLBU2 (5-90 μM, 24 h (abiotic surface); 10-100 μM, 5 h (CFAECs)) prevents abiotic P. aeruginosa biofilms on an abiotic surface and on human cystic fibrosis airway epithelial cells (CFAECs)^[1].
WLBU2 (50 μM, 5 h) retains biofilm prevention activity in high salt (100 mM Nacl) and low pH (6.5-7.0) environments in CFAECs^[1].
WLBU2 (20 μM, 5 h) shows synergistic effect when combined with Tobramycin (HY-B0441), ciprofloxacin (HY-B0356), Ceftazidime (HY-B0593), and Meropenem (HY-13678), but has no synergistic effect with Colistin (HY-113678) in CFAECs^[1].
WLBU2 exhibits a MIC value of 7.943 μM against Klebsiella pneumoniae and a MIC value of 7.484 μM against clinical isolates of Acinetobacter baumannii, with the MBC values of the bacterial isolates being identical to their respective MIC values, indicating its bactericidal effect^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3400.11

C₁₅₁H₂₆₀N₆₆O₂₅

847061-43-2

Arg-Arg-Trp-Val-Arg-Arg-Val-Arg-Arg-Trp-Val-Arg-Arg-Val-Val-Arg-Val-Val-Arg-Arg-Trp-Val-Arg-Arg

RRWVRRVRRWVRRVVRVVRRWVRR

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Lashua LP, et al. Engineered cationic antimicrobial peptide (eCAP) prevents Pseudomonas aeruginosa biofilm growth on airway epithelial cells. J Antimicrob Chemother. 2016 Aug;71(8):2200-7.  [Content Brief]

  [2]. Elsalem L, Khasawneh A, Al Sheboul S. WLBU2 Antimicrobial Peptide as a Potential Therapeutic for Treatment of Resistant Bacterial. Turk J Pharm Sci. 2022 Feb 28;19(1):110-116.